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H
epatorenal syndrome (HRS) is a serious complication of end-stage liver disease, occurring
mainly in patients with advanced cirrhosis and ascites, who have marked circulatory
dysfunction,1 as well as in patients with acute liver failure.2 In spite of its functional nature,
HRS is associated with a poor prognosis,3 4 and the only effective treatment is liver transplantation.
During the 56th Meeting of the American Association for the Study of Liver Diseases, the
International Ascites Club held a Focused Study Group (FSG) on HRS for the purpose of reporting
the results of an international workshop and to reach a consensus on a new definition, criteria for
diagnosis and recommendations on HRS treatment. A similar workshop was held in Chicago in 1994
in which standardised nomenclature and diagnostic criteria for refractory ascites and HRS were
established.5 The introduction of innovative treatments and improvements in our understanding of
the pathogenesis of HRS during the previous decade led to an increasing need to undertake a new
consensus meeting. This paper reports the scientific rationale behind the new definitions and
recommendations.
The international workshop included four issues debated by four panels of experts (see
Acknowledgements). The issues were: (1) evidence-based HRS pathogenesis; (2) treatment of HRS
using vasoconstrictors; (3) other HRS treatments using transjugular intrahepatic portosystemic
stent-shunt (TIPS) and extracorporeal albumin dialysis (ECAD); and (4) new definitions and
diagnostic criteria for HRS and recommendations for its treatment.
BACKGROUNDc
The definition and diagnostic criteria for HRS established in 19945 were based on the following three
concepts:
(1) renal failure in HRS is functional and caused by marked intrarenal arteriolar vasoconstriction;
(2) HRS occurs in patients with systemic circulatory dysfunction caused by extra-renal vasodilata-
tion;
(3) plasma volume expansion does not improve renal failure.
Four new concepts have emerged since then, these are:
(a) Extra-renal arterial vasodilatation occurs mainly in the splanchnic vascular bed, whereas other
vascular beds, such as those which supply the brain and the liver, may be vasoconstricted. This may
contribute to the development of hepatic encephalopathy and hepatic failure, respectively.
(b) Cardiac output in patients with HRS may be low, normal or high, but it is insufficient for the
patient’s needs because of reduced peripheral resistances.
(c) The most common trigger for the development of type-1 HRS is bacterial infection, mainly
spontaneous bacterial peritonitis (SBP).
(d) Renal function can be improved by medical treatment in patients with HRS and is associated
with improved survival.
Background for the new concepts
The first of these concepts was formulated following investigation conducted using Doppler
ultrasonography or plethysmography both before and after 1994. These studies were performed in
patients with varying degrees of severity of cirrhosis, and revealed arterial vasodilatation in the
splanchnic circulation as well as arterial vasoconstriction in other areas such as the brain, kidneys
and liver,6–13 whereas the cutaneous and muscular blood flow has been reported as low, normal or
increased.13–16 The dilatation of the splanchnic vessels is mainly caused by local release of potent
vasodilators such as nitric oxide (NO),17 which also render the splanchnic circulation resistant to
various vasopressors including angiotensin II, norepinephrine, vasopressin and endothelin.18–24 The
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resistance of the splanchnic circulation to these vasopressor
agents renders the control of arterial pressure in cirrhosis
dependent on the extra-splanchnic effects exerted by the
endogenous vasoconstrictor systems. As arterial vasodilatation
increases with progression of cirrhosis, the role of vasoconstrictors
in maintaining haemodynamic stability becomes critical, and
explains why cirrhotic patients with HRS are predisposed to
develop renal, hepatic and cerebral vasoconstriction.
The second new concept—that is, that insufficient cardiac
output contributes to renal hypoperfusion in patients with
HRS—was first suggested by Tristani and Cohn,25 but it is only
recently that this has been confirmed.26 27 The first study
showed that the cardiac output of cirrhotic patients with SBP
who developed progressive renal failure was relatively low,
despite resolution of infection, when compared with a similar
group of patients with SBP who did not develop renal failure.26
The second study compared non-azotaemic cirrhotic patients
who developed HRS with similar patients who did not, and
showed that low cardiac output and high plasma renin activity
(PRA) were independent predictors of HRS.27 Moreover, in
patients developing HRS, the progression of circulatory
dysfunction leading to arterial hypotension and renal failure
occurred in the setting of a continued decrease in cardiac
output and increase in PRA. These findings support the
hypothesis that hyperdynamic circulation is essential to
maintain central blood volume and renal perfusion in cirrhosis.
Therefore, when cardiac output decreases, effective hypovolae-
mia occurs, leading to renal hypoperfusion and HRS. The
mechanism leading to impaired or insuffient cardiac output in
patients developing HRS is unknown. In recent years, a specific
cardiac abnormality, characterised by attenuated systolic and
diastolic responses to stimuli, changes in repolarisation and
hypertrophy of the cardiac chambers, has become increasingly
recognised—the so-called ‘‘cirrhotic cardiomyopathy’’.28 A fall
in cardiac preload due to a decrease in venous return is another
hypothesis that might justify the effectiveness of albumin
infusion.27
HRS can be triggered by precipitating events. The most
important of these are infection, bleeding and large-volume
paracentesis without albumin administration.29–32 The role of
SBP has recently been emphasised. Table 1 compares the results
of two studies29 30 assessing the prevalence of renal failure in
cirrhotic patients with SBP and in those with infections
unrelated to SBP, and shows that: (a) in spite of an effective
antibiotic therapy, a significant proportion of cirrhotic patients
with bacterial infection develop progressive renal failure. This
almost exclusively occurs in patients with SBP; (b) in patients
not responsive to antibiotic therapy, progressive renal failure
occurs and is independent of the type of infection. Furthermore,
changes in circulatory function, endogenous vasoactive systems
and renal function in patients developing renal failure triggered
by SBP are identical to those observed in patients with HRS
unrelated to infection, suggesting that the pathogenesis of
progressive renal failure in cirrhotic patients with infection is
the same as that of HRS.
The most important concept of HRS, however, arises from
studies exploring new therapeutic strategies.33 Since type-1 HRS
is often associated with a rapid deterioration of liver function
with increased levels of bilirubin and prothrombin time, it has
traditionally been viewed as a manifestation of terminal hepatic
failure. The demonstration that type-1 HRS can be improved by
vasoconstrictors34 or by TIPS,35 36 and that reversal of type-1
HRS may be associated with improved survival, represents a
major change in our understanding of the syndrome.
In conclusion, the main pathogenic mechanism in type-1
HRS is a potentially reversible deterioration of systemic
circulatory function, mostly due to splanchnic vasodilatation
and renal vasoconstriction and often triggered by a precipitat-
ing event (fig 1). In addition to renal failure, the syndrome may
be associated with other organ dysfunctions, such as decreased
cardiac output, hepatic failure and encephalopathy.
TREATMENT OF HRS
New treatments of HRS are designed to expand the central
blood volume by simultaneously increasing the total plasma
volume and reducing intense peripheral vasodilatation. This
strategy is not entirely new, as in 1967 Tristani and Cohn25
showed that dextran infusion improved cardiac output and
Main pathophysiological and clinical aspects of
HRS
c HRS is a functional renal failure caused by intrarenal
vasoconstriction which occurs in patiens with end-stage liver
disease and circulatory dysfunction.
c Circulatory dysfunction is characterised by vasodilatation in
the splanchnic circulation with a relatively low and
insufficient cardiac output, leading to effective hypovolae-
mia.
c HRS may occur spontaneously with worsening liver function,
or secondary to a precipitating event such as bacterial
infection (eg, SBP).
c HRS can be improved by the administration of vasocon-
strictors and albumin, or by TIPS.
Table 1 Incidence and course of renal failure in cirrhotic patients with severe bacterial
infections without shock according to response to antibiotic treatment and to type of infection
No response Response
SBP (n = 21)*
Sepsis unrelated to
SBP (n = 9) SBP (n = 231)*
Sepsis unrelated to
SBP (n = 98)
No renal failure 3 (14%) 2 (22%) 166 (71%) 77 (78%)
Transient renal failure 0 (0%) 0 (0%) 21 (9%) 22 (22%)
Steady renal failure 1 (5%) 2 (22%) 26 (11%) 0 (0%)
Progressive renal failure 17 (81%) 5 (55%) 18 (7%) 1 (1%)
*Data on spontaneous bacterial peritonitis (SBP) are from Follo et al.29
Data on sepsis unrelated to SBP are from Terra et al.30
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renal perfusion in oliguric cirrhotic patients, and 18 years later
Shapiro et al37 showed that the urine water and sodium excretion
in cirrhotic patients with ascites was improved by the adminis-
tration of norepinephrine combined with head-out water immer-
sion, a manoeuvre aimed at expanding central blood volume.
However, clinically relevant results have only been obtained more
recently with the use of albumin and various vasoconstrictors.
The mechanism by which vasoconstrictors and albumin
improve the glomerular filtration rate (GFR) in patients with
HRS is incompletely understood. Nevertheless, administration
of terlipressin to patients with HRS increases blood pressure
and leads to a significant decrease in PRA and increase in
GFR,38 indirectly indicating correction of circulatory dysfunc-
tion. It is conceivable that vasopressin analogues cause
vasoconstriction of the splanchnic bed, thereby allowing
redistribution of the blood volume to some of the extra-
splanchnic organs including the central compartment and the
kidneys. Filling of the central compartment will lead to the
inhibition of the sympathetic nervous and renin–angiotensin
systems, thereby shifting the autoregulatory curve to the left
and making renal blood flow and GFR more responsive to
changes in blood pressure.39 40 Albumin is traditionally con-
sidered to improve circulatory function in cirrhosis by expand-
ing central blood volume and increasing cardiac output.41
Moreover, recent studies have shown that the administration
of albumin to cirrhotic patients with SBP causes arterial
vasoconstriction and blood pressure increase,42 probably attri-
butable to the ability of albumin to bind vasodilators. It is
therefore conceivable that an improvement of renal function in
patients with HRS treated with vasoconstrictors and albumin is
due to the additive effects that the two compounds have on
cardiac function and peripheral arterial circulation.
Prophylaxis of HRS
One randomised controlled trial (RCT) showed that albumin
prevented type-1 HRS in patients with SBP.41 Patients receiving
albumin (1.5 g/kg body weight on the first day plus 1 g/kg body
weight on the third day) showed a 66% reduction in the
incidence of HRS (10% vs 33%) and a significant reduction of
in-hospital and 3-month mortality rates (10% vs 29%, p,0.01,
and 22% vs 41%, p,0.03, respectively,). The albumin effect was
related to an improvement in systemic haemodynamics, as
indicated by PRA suppression. Indeed, albumin infusion in
cirrhotic patients with SBP improves both cardiac function and
systemic vascular resistance.43 As type-1 HRS almost exclusively
occurred in patients with serum bilirubin .68 mmol/l (4 mg/dl)
and serum creatinine .88.4 mmol/l (1 mg/dl), the prophylactic
use of albumin could probably be restricted to these patients,
but trials need to be conducted so that the optimum dosage to
be used can be defined more precisely.
New treatments of HRS
Vasoconstrictors and albumin
The use of an analogue of vasopressin to improve renal blood
flow in cirrhotic patients was first proposed by Kew et al 35
years ago.44 More recently, Lenz et al45 showed that GFR may be
moderately improved by ornipressin infusion in patients with
HRS, but the drug was given for only 4 h, therefore precluding
assessment of its long-term effects. Two more studies demon-
strated that a long-term (1–2 weeks) infusion of ornipressin,
combined with albumin or dopamine, normalised serum
creatinine concentrations in many patients with type-1
HRS.34 46 Interestingly, recurrence of renal failure rarely
occurred after treatment withdrawal, and in the few cases
where it did recur a second course of therapy was successful.
However, the drawback with ornipressin was the frequent
occurrence of ischaemic complications.34 46
Therefore, widespread use of vasoconstrictors in patients
with HRS has only become clinically feasible with the advent of
safer compounds such as terlipressin,47–49 a vasopressin analo-
gue with longer activity, and the a2-agonist midodrine
combined with octreotide.50 51 Table 2 summarises the data
Figure 1 Schematic view of the
pathogenetic mechanisms of
hepatorenal syndrome in cirrhosis.
Dotted arrows indicate that precipitating
factors are frequent but not necessary.
RAAS, renin–angiotensin–aldosterone
system; SBP, spontaneous bacterial
peritonitis; SNS, sympathetic nervous
system.
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available on the use of terlipressin in type-1 HRS. They include
four RCTs,38 48 52 53 and many pilot or retrospective studies.
These studies show that: (a) although GFR rarely reaches
normal levels, a short period of treatment with terlipressin
improves renal function in up to 65% of patients with type-1
HRS; (b) the effectiveness of terlipressin is probably enhanced
by albumin;49 (c) HRS recurs after treatment withdrawal in
approximately 20% of patients, but re-treatment is often
effective; (d) in most cases, dilutional hyponatraemia asso-
ciated with HRS improves with terlipressin treatment;48 49 (e)
severe side effects of the treatment are uncommon (5–10%).
With regards to survival, patients who experienced a complete
reversal of type-1 HRS by terlipressin seem to have improved
short-term survival, although the RCT of Sanyal53 reported
similar survival at 60 days of follow-up between patients
treated with terlipressin plus albumin and those treated only
with albumin. Therefore, the long-term survival of patients
with type-1 HRS treated with terlipressin merits further
investigation. Nevertheless, using terlipressin to improve renal
function is an important support resource for patients included
on a liver transplant waiting list who develop type-1 HRS.54
The initial dose of terlipressin in many studies ranged from
0.5 to 1 mg every 4–6 h. This regimen was maintained until
reversal of HRS, which usually occurred within the second
week of treatment.47 52 In other studies, the initial dose in cases
without an early response was increased up to 2 mg every 4–
6 h.49 The daily dose of albumin was generally 20–40 g,
preceded in some studies by a load of 1 g/kg body weight.
Some refer to central venous pressure to establish and titrate
albumin doses and to prevent fluid overload.
Experience of using midodrine in patients with type-1 HRS is
more limited. To date, there have been two pilot studies.50 51 In
both, midodrine was combined with octreotide to enhance the
effect of splanchnic vasoconstriction, but doses and routes of
administration were quite different. Angeli et al50 used 7.5–
12.5 mg of oral or intravenous midodrine three times a day plus
100–200 mg of subcutaneous octreotide three times a day,
whereas Wong et al51 used 2.5 mg of oral midodrine three times
a day plus an intravenous infusion of octreotide (25 mg/h after a
bolus of 25 mg). The dose of midodrine was adjusted to increase
mean arterial pressure to 90 mm Hg. Albumin was also
administered to patients in these studies. The results are
similar to those observed with terlipressin, although the
response was slower. Since octreotide alone had no impact on
GFR in patients with HRS,55 it is likely that midodrine plays the
main role in improving GFR.
A pilot study has also explored the effect of norepinephrine
infusion (0.5–3 mg/h) combined with albumin and furosemide
in type-1 HRS.56 The doses were titrated to increase mean
arterial pressure by 10 mm Hg. Reversal of HRS was achieved in
10 out of 12 cases and was associated with improvement in
urinary sodium excretion and decrease in PRA. Norepinephrine
is cheaper and more widely available than terlipressin, but it is
thought to have a greater propensity to induce cardiac
arrhythmias. Therefore, the role of norepinephrine in patients
with type-1 HRS still needs to be established on the basis of
future comparisons with terlipressin or midodrine/octreotide.
Only a few patients with type-2 HRS have been specifically
treated using terlipressin and albumin.33 In most cases,
normalisation of serum creatinine was observed, but, in
contrast to type-1 HRS, renal failure invariably recurred after
treatment withdrawal.
Transjugular intrahepatic portosystemic stent-shunt
Only a few studies have assessed the role of TIPS in HRS—91
patients in total. Most were prospective but uncontrolled
studies.35 36 51 57 58 Three were performed in patients with type-
1 HRS,35 36 51 one in patients with type-1 or type-2 HRS,57 and
the last specifically investigated type-2 HRS.58 The following can
be observed:
(a) significant suppression of the endogenous vasoactive
systems, particularly the renin–angiotensin system,35 and a
Table 2 Characteristics and results of studies reporting the effect of terlipressin in patients with
cirrhosis and type-1 HRS
Author, year (reference)
Type of
study
Success rate of
therapy
Dose (mg/
day)
Duration
(days)
Survival at
4 weeks*
Adverse
events
Ganne-Carrie, 199677 C 1/1 2 67 Yes Yes
Le Moine, 199878 C 1/1 6 30 Yes No
Duhamel, 200079 R 6/12 2–6 3–10 9/18 4/12
Colle, 200280 R 11/18 2.8 (0.1) 9 (1) 1/16 0/18
Halimi, 200281 R 12/16 1.5–12 2–16 3/7 4/16
Moreau, 200247 R 53/99 3.2 (1.2) 11 (12) 37/99 23/99
Danalioglu, 200382 R 3/7 2–4 3–14 ND No
Uriz, 200048 PU 4/6 3–6 5–15 4/6 1/6
Mulkay, 200183 PU 12/12 1–6 8–14 3/12 4/12
Angeli, 200684 PU 12/19 2–12 (15 13/19 ND
Ortega, 200249 PU T+A: 8/9 2 4–14 8/9 1/16
T: 1/7 1/7
Hadengue, 199838 RCT 6/9 2 2 ND 0/9
Solanki, 200352 RCT T: 5/12 2 14 nd 5/12
P: 0/12
Sanyal, 200653 RCT T+A: 19/56 4–8 14 27/56
A: 7/56 27/56
Total 154/284 2–12 3–67 108/251 43/209
C, case report; R, retrospective; PU, prospective uncontrolled; PC, prospective controlled; RCT, randomised controlled
trial; ND, not determined.
*Success rate of therapy means partial or complete response in terms of renal function. T+A, terlipressin+albumin; T,
terlipressin; P, placebo; A, albumin.
Survival was reported at 60 days.
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decrease of creatinine levels were recorded after TIPS in
most patients with type-1 HRS. The rate of the creatinine
decrease was slower than is usually obtained using
terlipressin plus albumin;
(b) recurrence of HRS was rare, provided that there was no
shunt malfunction;
(c) hepatic encephalopathy was a frequent complication of
TIPS but was adequately managed by medical treatment;
(d) TIPS almost always induced a reduction of ascites volume;
(e) resolution of type-1 HRS by TIPS can improve survival;
(f) sequential treatment with vasoconstrictors and albumin
followed by TIPS could be used as an alternative approach
to increasing the probability of long-term success;51
(g) although TIPS may improve renal function and refractory
ascites in patients with type-2 HRS, its effect on survival is
still undefined.
However, since almost all studies excluded patients with a
history of severe encephalopathy, serum bilirubin levels
.85 mmol/l (5 mg/dl), or Child–Pugh score .12, the applicability
of TIPS may be rather limited in patients with HRS who frequently
show jaundice, encephalopathy and high Child–Pugh scores.59
There has been little investigation into the mechanism
through which TIPS exerts beneficial effects in patients with
HRS. Nevertheless, as TIPS functions as a side-to-side
portocaval shunt, it is expected to relieve portal hypertension,
which plays a pivotal role in the pathogenesis of splanchnic
arterial vasodilatation.60 Moreover, TIPS insertion is associated
with an increase in cardiac output and an expansion in central
blood volume.61 62 The simultaneous effects on the splanchnic
and systemic circulation may represent the mechanism by
which TIPS improves renal perfusion, GFR, urine sodium and
water excretion, and hyponatraemia.63
Extracorporeal albumin dialysis (ECAD)
This procedure uses a cell-free albumin-containing dialysate
that is re-circulated and perfused through charcoal and anion
exchange columns (molecular adsorbent recycling system
(MARS)). The system is also connected to a haemodialysis or
haemoperfusion apparatus. ECAD enables the removal of
albumin-bound substances, including bilirubin, bile acids,
aromatic amino acids, medium chain fatty acids and cyto-
kines.64 There are few data available for ECAD in cirrhotic
patients with HRS, and these data are controversial.65 66 ECAD
decreases serum creatinine levels, but it is not definitively
known whether or not this effect is due to a true improvement
of renal function or simply to the filtration process. A few
studies reported that systemic haemodynamics improved
during ECAD, indicated by an increase in arterial pressure
and systemic vascular resistances, and a decrease in cardiac
output, PRA and norepinephrine levels. However, studies
regarding the effect of ECAD on survival in patients with
type-1 HRS included too few patients to draw any definite
conclusions.66 67 Moreover, ECAD is a very expensive procedure
and should still therefore be considered experimental.
Liver transplantation in patients with HRS
Liver transplantation was the only effective therapy for patients
with HRS before the introduction of vasoconstrictors and TIPS,
and is still the treatment of choice for these patients.68–71
Further impairment in GFR may be observed immediately after
liver transplantation, and many patients require long-term
dialysis (35% of transplanted patients with HRS vs 5% of
transplanted patients without HRS).68 71 As calcineurin inhibi-
tors (ciclosporin and tacrolimus) may contribute to GFR
impairment, it is suggested to delay their administration until
a partial recovery of renal function is recorded, usually 48–72 h
after transplantation. After this early impairment, GFR starts to
improve until an average value of 30–40 ml/min is reached 1–
2 months postoperatively. This moderate renal failure persists
during the follow-up and is probably due to an enhanced
nephrotoxic effect of calcineurin inhibitors in patients with pre-
transplant renal impairment. In fact, the haemodynamic and
neurohormonal abnormalities associated with HRS disappear
within the first month after transplantation, and the patients
regain their ability to excrete sodium and free water.72
Patients with HRS who undergo liver transplantation tend to
have more complications, spend more days in intensive care
units and have higher in-hospital mortality rates than liver
transplant patients without HRS.73 74 However, their 3-year
probability of survival is acceptable (60% vs 70–80% in liver
transplant patients without HRS).70
The main limitation of liver transplantation is that due to the
shortage of donor organs, and their extremely short survival,
most patients with type-1 HRS die before transplantation. The
introduction of the model of end-stage liver disease (MELD) for
organ prioritisation has partially solved this problem, since
patients with HRS are generally given high priority on the
waiting list. On the other hand, treatment of type-1 HRS with
vasoconstrictors and albumin (see above) can improve patient
survival, and therefore improve their probability of being
transplanted. In one non-randomised pilot study, reversal of
type-1 HRS using terlipressin and albumin was associated with
reduction in early morbidity and mortality after liver trans-
plantation.54
CONCLUSIONS OF THE CONSENSUS WORKSHOP
Improved knowledge of the mechanisms underlying HRS and
the development of new treatment strategies are the reasons for
Effective treatments of type-1 HRS
c Albumin infusion may prevent HRS in patients with SBP.
c Vasoconstrictors and albumin are recommended as the first
line of treatment for type-1 HRS. Terlipressin is the most
widely used vasoconstrictor. Midodrine+octreotide and
norepinephrine are two possible alternatives requiring
further clinical evaluation.
c With the use of terlipressin (2–12 mg/day) and albumin
(20–40 g/day after 1 g/kg on the first day), about 60% of
renal failure cases recover. The improvement of survival
using only vasoconstrictors and albumin seems rather
limited.
c TIPS is an alternative treatment in suitable patients,
especially in those who do not show a complete response
to vasoconstrictors, but it can also be used in patients who
show a complete serum creatinine response to eliminate
ascites and to maintain normal renal function.
c Liver transplantation is the only treatment that assures long-
term survival.
c Pharmacological treatment and TIPS can bridge the time to
liver transplantation and improve post-transplant survival.
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the new consensus on definition, diagnostic criteria and HRS
treatment modalities organised by the International Ascites
Club.
New definit ion of HRS
HRS is a potentially reversible syndrome that occurs in patients
with cirrhosis, ascites and liver failure, as well as in patients
with acute liver failure or alcoholic hepatitis. It is characterised
by impaired renal function, marked alterations in cardiovas-
cular function and overactivity of the sympathetic nervous and
renin–angiotensin systems. Severe renal vasoconstriction leads
to a decrease of GFR. There are two types of HRS. Type-2 HRS is
characterised by moderate renal failure (serum creatinine from
133 to 226 mmol/l or from 1.5 to 2.5 mg/dl), with a steady or
slowly progressive course. It appears spontaneously, but can
also follow a precipitating event. Type-2 HRS is typically
associated with refractory ascites. Survival of patients with
type-2 HRS is shorter than that of non-azotaemic cirrhotic
patients with ascites but better than that of patients with type-1
HRS (fig 2).75
Type-1 HRS is characterised by rapid progressive renal failure
defined by doubling of the initial serum creatinine concentra-
tions to a level greater than 226 mmol/l (2.5 mg/dl) in less than
2 weeks. It may appear spontaneously, but often develops after
a precipitating event, particularly SBP. Type-1 HRS usually
occurs within the setting of an acute deterioration of circulatory
function characterised by arterial hypotension and activation of
endogenous vasoconstrictor systems, and may be associated
with impaired cardiac and liver functions as well as encephalo-
pathy. The natural prognosis of type-1 HRS is very poor (fig 2).
The main differences from the definition reported in 19965
are:
(a) the potential reversibility of HRS without liver transplan-
tation;
(b) the dominant role of the splanchnic bed in arterial
vasodilatation;
(c) the frequent role of SBP as an event precipitating type-1
HRS;
(d) the concept that in addition to renal failure the function of
other organs, particularly the heart, is frequently impaired.
Revised diagnostic criteria of HRS
As there are no specific hallmarks of HRS, the diagnosis is
based on the exclusion of other types of renal failure. The
criteria necessary to diagnose HRS are reported in the box
below.
The main differences between these criteria and those
previously established5 are:
(a) creatinine clearance has been excluded because it is more
complicated than simple serum creatinine for routine
purposes, and it does not increase the accuracy of renal
function estimation in cirrhotic patients;76
(b) renal failure in the setting of ongoing bacterial infection,
but in the absence of septic shock, is now considered HRS.
This means treatment of HRS can be started without
waiting for complete recovery from the infection;
(c) plasma volume expansion should be performed with
albumin rather than saline. Members of the panel agreed
that albumin causes a greater and more sustained expan-
sion than saline;
(d) minor diagnostic criteria have been removed as they are not
essential.
Treatments of HRS
Most data currently available on HRS treatments come from
retrospective analyses, pilot studies, non-randomised compara-
tive studies and only a few RCTs. Furthermore, most studies
have included too few patients. Therefore, concepts and
practical recommendations given in this part of the article are
based on both published data and the personal experience of
the panelists, and may be improved upon by further experience
gained in the future
Prevention of HRS
The incidence of HRS in patients with SBP may be reduced by
albumin administration, prevention which was associated with
improved survival. The suggested dose of albumin is 1.5 g/kg
body weight on the first day and 1 g/kg body weight on the
third day, up to a maximum of 150 and 100 g, respectively.
Albumin administration is clearly indicated for patients with
SBP and serum bilirubin levels .68.4 mmol/l (4 mg/dl) or
Figure 2 Actuarial probability to survive in cirrhotic patients with
different renal impairments: non-azotaemic patients (continuous line);
patients with hepatic renal syndrome (HRS) type-2 (dotted line) and
patients with HRS type-1 (red line). Adapted from Alessandria et al75.
New diagnostic hepatorenal syndrome criteria in
cirrhosis
c Cirrhosis with ascites.
c Serum creatinine .133 mmol/l (1.5 mg/dl).
c No improvement of serum creatinine (decrease to a level of
(133 mmol/l) after at least 2 days with diuretic withdrawal
and volume expansion with albumin. The recommended
dose of albumin is 1 g/kg of body weight per day up to a
maximum of 100 g/day.
c Absence of shock.
c No current or recent treatment with nephrotoxic drugs.
c Absence of parenchymal kidney disease as indicated by
proteinuria .500 mg/day, microhaematuria (.50 red
blood cells per high power field) and/or abnormal renal
ultrasonography.
1315
HEPATORENAL SYNDROME
www.gutjnl.com
 group.bmj.com on April 4, 2011 - Published by gut.bmj.comDownloaded from 
serum creatinine levels .88.4 mmol/l (1 mg/dl). Future studies
are necessary to define better optimal doses of albumin and the
subgroup of patients for whom treatment is highly indicated.
Effective treatments of HRS
Liver transplantation
This is the treatment of choice for both type-1 and type-2 HRS.
Morbidity after liver transplantation is higher in patients with
HRS than in those without HRS,74 although the long-term
probability of survival is only slightly lower. Reversal of type-1
HRS by pharmacological treatment before liver transplantation
may improve survival after transplantation. The reduction in
serum creatinine levels after treatment and the related decrease
in the MELD score should not change the decision to perform
liver transplantation since the prognosis after recovering from
type-1 HRS is still very poor.
Pharmacological treatment with vasoconstrictors
Studies on the pharmacological treatment of HRS have mainly
been performed in patients with type-1 HRS. Terlipressin is the
most widely studied compound. It should be started at 0.5–
1 mg every 4–6 h. If there is no early response (.25% decrease
in creatinine levels after 2 days), the dose can be doubled every
2 days up to a maximum of 12 mg/day. Treatment can be
stopped if serum creatinine does not decrease by at least 50%
after 7 days of the highest dose, or if there is no reduction after
the first 3 days. In patients with early response, treatment
should be extended until reversal of HRS (see text box) or for a
maximum of 14 days. Terlipressin may induce ischaemic side
effects and arrhythmias requiring drug discontinuation.33
Other vasoconstrictors tested in HRS are midodrine, in
combination with octreotide, or norepinephrine. The schedules
for midodrine and octreotide and those of norepinephrine are
reported above.
In addition to creatinine levels being useful in adjusting the
doses of these vasoconstrictors, blood pressure, renal water and
sodium excretion, and serum sodium levels may also be helpful.
The administration of albumin may improve the effect of
vasoconstrictors. In the absence of dose/effect studies, the dose
of albumin recommended is 1 g/kg of body weight on the first
day, up to a maximum of 100 g, followed by 20–40 g/day.
Albumin may be discontinued if serum albumin concentration
is .45 g/l and should be withdrawn in the case of pulmonary
oedema. Since this complication is uncommon, catheterisation
to monitor central venous pressure is not mandatory, but
careful physical and radiological monitoring of the cardiopul-
monary function is recommended.
As reported in the text box, three types of response to
treatment with vasoconstrictors and albumin can be observed.
Complete response occurs in approximately 60% of patients
treated with terlipressin and can improve survival. Renal failure
may recur after discontinuation of therapy (relapse), but
retreatment is usually effective. In contrast, partial response
is frequently followed by a severe and irreversible relapse of
renal failure.
TIPS
The small amount of data on the use of TIPS in HRS shows that
it improves renal function and eliminates ascites. In patients
with type-1 HRS, TIPS may also improve survival, but this is
debatable in patients with type-2 HRS. The major disadvantage
of TIPS is its low applicability. Indeed, it should not be used in
patients with serum bilirubin levels .85.5 mmol/l (5 mg/dl),
severe encephalopathy or history of recurrent encephalopathy,
severe bacterial infection, serious cardiac or pulmonary
dysfunction or a Child–Pugh score .11.
Final recommendations for the treatment of patients
with HRS
Type-1 HRS
The first line of therapy is the use of vasoconstrictors combined
with albumin. Patients with partial or no response to
vasoconstrictors may be treated with TIPS. If there are
contra-indications to TIPS, ECAD could be used in the setting
of prospective trials.
The sequential use of vasoconstrictors plus albumin and TIPS
in suitable patients is an interesting idea deserving further
investigation.
Type-2 HRS
There are no definite data to support the use of vasoconstrictors
in these patients. TIPS can be used to improve refractory ascites,
which is often associated with type-2 HRS. Data on the effect of
TIPS on survival are still insufficient.
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